title: Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.
abstract: OBJECTIVE
  To compare the effect of the gonadotrophin-releasing hormone agonist leuprorelin and progestin lynestrenol, given prior to surgical treatment of symptomatic uterine myomas, on the pre-operative symptoms, tolerance, and operative blood loss.
  
  
  METHODS
  Fifty-six women were randomly selected to receive, during 16 weeks, either monthly subcutaneous injections of leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs per day (5th to the 25th menstrual cycle) (n=23).
  
  
  RESULTS
  Intent-to-treat analysis of the main efficacy criterion, namely ultrasonographic reduction of myoma(s) diameter, showed a significant difference in favour of leuprorelin (P=0.02) with a mean decrease of 26.5+/-4.5% (n=29) as opposed to 7.3+/-5% in the lynestrenol group (n=17). Clinical improvement was satisfactory in both groups. Hematocrit decrease between the preoperative value and the value measured 48 h postoperatively was significantly lower in the leuprorelin group than in the lynestrenol one (P=0.02) (for hemoglobin: P=0.07).
  
  
  CONCLUSIONS
  Leuprorelin was more effective than lynestrenol because of its more intense antigonadotropic activity. The tolerance was good, reflecting each drug mechanism of action.
authors.affiliation: Department of Obstetrics and Gynecology, Rouen University Hospital, France. verspyck@chu-rouen.fr
authors.forename: E
authors.initials: E
authors.lastname: Verspyck
authors.forename: L
authors.initials: L
authors.lastname: Marpeau
authors.forename: C
authors.initials: C
authors.lastname: Lucas
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007889:Leiomyoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008234:Lynestrenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011300:Preoperative Care; D014463:Ultrasonography; D014594:Uterine Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide; D008234:Lynestrenol